411 related articles for article (PubMed ID: 28393693)
1. Update on the Protective Renal Effects of Metformin in Diabetic Nephropathy.
Eisenreich A; Leppert U
Curr Med Chem; 2017; 24(31):3397-3412. PubMed ID: 28393693
[TBL] [Abstract][Full Text] [Related]
2. Metformin modulates apoptosis and cell signaling of human podocytes under high glucose conditions.
Langer S; Kreutz R; Eisenreich A
J Nephrol; 2016 Dec; 29(6):765-773. PubMed ID: 26733332
[TBL] [Abstract][Full Text] [Related]
3. Metformin attenuates streptozotocin-induced diabetic nephropathy in rats through modulation of oxidative stress genes expression.
Alhaider AA; Korashy HM; Sayed-Ahmed MM; Mobark M; Kfoury H; Mansour MA
Chem Biol Interact; 2011 Jul; 192(3):233-42. PubMed ID: 21457706
[TBL] [Abstract][Full Text] [Related]
4. Mechanism and application of metformin in kidney diseases: An update.
Song A; Zhang C; Meng X
Biomed Pharmacother; 2021 Jun; 138():111454. PubMed ID: 33714781
[TBL] [Abstract][Full Text] [Related]
5. Bright renoprotective properties of metformin: beyond blood glucose regulatory effects.
Nasri H; Baradaran A; Ardalan MR; Mardani S; Momeni A; Rafieian-Kopaei M
Iran J Kidney Dis; 2013 Nov; 7(6):423-8. PubMed ID: 24241085
[TBL] [Abstract][Full Text] [Related]
6. Nephroprotective Effects of Metformin in Diabetic Nephropathy.
Ravindran S; Kuruvilla V; Wilbur K; Munusamy S
J Cell Physiol; 2017 Apr; 232(4):731-742. PubMed ID: 27627216
[TBL] [Abstract][Full Text] [Related]
7. Effect of coenzyme Q10 alone and its combination with metformin on streptozotocin-nicotinamide-induced diabetic nephropathy in rats.
Maheshwari RA; Balaraman R; Sen AK; Seth AK
Indian J Pharmacol; 2014; 46(6):627-32. PubMed ID: 25538335
[TBL] [Abstract][Full Text] [Related]
8. Metformin reduces TRPC6 expression through AMPK activation and modulates cytoskeleton dynamics in podocytes under diabetic conditions.
Szrejder M; Rachubik P; Rogacka D; Audzeyenka I; Rychłowski M; Kreft E; Angielski S; Piwkowska A
Biochim Biophys Acta Mol Basis Dis; 2020 Mar; 1866(3):165610. PubMed ID: 31778750
[TBL] [Abstract][Full Text] [Related]
9. Metformin attenuates albumin-induced alterations in renal tubular cells in vitro.
Allouch S; Munusamy S
J Cell Physiol; 2017 Dec; 232(12):3652-3663. PubMed ID: 28158902
[TBL] [Abstract][Full Text] [Related]
10. Beneficial effects of metformin on glomerular podocytes in diabetes.
Rogacka D; Piwkowska A
Biochem Pharmacol; 2021 Oct; 192():114687. PubMed ID: 34274355
[TBL] [Abstract][Full Text] [Related]
11. Exogenous spermine attenuates diabetic kidney injury in rats by inhibiting AMPK/mTOR signaling pathway.
Zhang X; Zhang L; Chen Z; Li S; Che B; Wang N; Chen J; Xu C; Wei C
Int J Mol Med; 2021 Mar; 47(3):. PubMed ID: 33537831
[TBL] [Abstract][Full Text] [Related]
12. Metformin inhibits advanced glycation end products (AGEs)-induced renal tubular cell injury by suppressing reactive oxygen species generation via reducing receptor for AGEs (RAGE) expression.
Ishibashi Y; Matsui T; Takeuchi M; Yamagishi S
Horm Metab Res; 2012 Nov; 44(12):891-5. PubMed ID: 22864903
[TBL] [Abstract][Full Text] [Related]
13. Role of Impaired Nutrient and Oxygen Deprivation Signaling and Deficient Autophagic Flux in Diabetic CKD Development: Implications for Understanding the Effects of Sodium-Glucose Cotransporter 2-Inhibitors.
Packer M
J Am Soc Nephrol; 2020 May; 31(5):907-919. PubMed ID: 32276962
[TBL] [Abstract][Full Text] [Related]
14. Glucagon-like peptide-1 alleviates diabetic kidney disease through activation of autophagy by regulating AMP-activated protein kinase-mammalian target of rapamycin pathway.
Yang S; Lin C; Zhuo X; Wang J; Rao S; Xu W; Cheng Y; Yang L
Am J Physiol Endocrinol Metab; 2020 Dec; 319(6):E1019-E1030. PubMed ID: 32985256
[TBL] [Abstract][Full Text] [Related]
15. Tubular injury in a rat model of type 2 diabetes is prevented by metformin: a possible role of HIF-1α expression and oxygen metabolism.
Takiyama Y; Harumi T; Watanabe J; Fujita Y; Honjo J; Shimizu N; Makino Y; Haneda M
Diabetes; 2011 Mar; 60(3):981-92. PubMed ID: 21282369
[TBL] [Abstract][Full Text] [Related]
16. Metformin enhances cisplatin cytotoxicity by suppressing signal transducer and activator of transcription-3 activity independently of the liver kinase B1-AMP-activated protein kinase pathway.
Lin CC; Yeh HH; Huang WL; Yan JJ; Lai WW; Su WP; Chen HH; Su WC
Am J Respir Cell Mol Biol; 2013 Aug; 49(2):241-50. PubMed ID: 23526220
[TBL] [Abstract][Full Text] [Related]
17. Renal podocyte injury in a rat model of type 2 diabetes is prevented by metformin.
Kim J; Shon E; Kim CS; Kim JS
Exp Diabetes Res; 2012; 2012():210821. PubMed ID: 23056035
[TBL] [Abstract][Full Text] [Related]
18. AMPK signalling: Implications for podocyte biology in diabetic nephropathy.
Szrejder M; Piwkowska A
Biol Cell; 2019 May; 111(5):109-120. PubMed ID: 30702162
[TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor receptor inhibition slows progression of diabetic nephropathy in association with a decrease in endoplasmic reticulum stress and an increase in autophagy.
Zhang MZ; Wang Y; Paueksakon P; Harris RC
Diabetes; 2014 Jun; 63(6):2063-72. PubMed ID: 24705402
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo inhibition of mTOR by 1,25-dihydroxyvitamin D
Wang H; Wang J; Qu H; Wei H; Ji B; Yang Z; Wu J; He Q; Luo Y; Liu D; Duan Y; Liu F; Deng H
Endocrine; 2016 Nov; 54(2):348-359. PubMed ID: 27395420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
